These companies offer promising pipelines that could deliver in the long term.
Compare APRE Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Aprea Therapeutics Inc
News & Analysis: Aprea Therapeutics Inc
Here's why this biotech company with a promising treatment for a rare blood disorder is a solid buy.
While IPOs allow companies to tap into capital markets, going public provides liquidity to early-stage investors seeking to unload stock positions.
The drug candidate is in phase 3 trials as a treatment of myelodysplastic syndrome (MDS), which often leads to blood and bone marrow cancers.
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
Three biotech companies successfully completed IPOs last week. Would investors have been better off buying shares on the open market?